Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

IL-6-specific autoantibodies among APECED and thymoma patients.

Kärner J, Pihlap M, Ranki A, Krohn K, Trebusak Podkrajsek K, Bratanic N, Battelino T, Willcox N, Peterson P, Kisand K.

Immun Inflamm Dis. 2016 May 25;4(2):235-243. eCollection 2016 Jun.

2.

Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJGM, Kostera-Pruszczyk A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L.

Mol Med. 2016 Mar;21(1):769-781. doi: 10.2119/molmed.2015.00232. Epub 2015 Nov 10.

3.

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.

Avidan N, Le Panse R, Harbo HF, Bernasconi P, Poulas K, Ginzburg E, Cavalcante P, Colleoni L, Baggi F, Antozzi C, Truffault F, Horn-Saban S, Pöschel S, Zagoriti Z, Maniaol A, Lie BA, Bernard I, Saoudi A, Illes Z, Casasnovas Pons C, Melms A, Tzartos S, Willcox N, Kostera-Pruszczyk A, Tallaksen C, Mantegazza R, Berrih-Aknin S, Miller A.

Ann Clin Transl Neurol. 2014 May;1(5):329-39. doi: 10.1002/acn3.51. Epub 2014 Apr 11.

4.

Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.

Wolff AS, Kärner J, Owe JF, Oftedal BE, Gilhus NE, Erichsen MM, Kämpe O, Meager A, Peterson P, Kisand K, Willcox N, Husebye ES.

J Immunol. 2014 Oct 15;193(8):3880-90. doi: 10.4049/jimmunol.1401068. Epub 2014 Sep 17.

5.

Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A, Duimel H, Verheyen F, Molenaar PC, Buurman WA, De Baets MH, Martinez-Martinez P, Losen M.

J Immunol. 2014 Aug 1;193(3):1055-1063. doi: 10.4049/jimmunol.1301555. Epub 2014 Jun 27.

6.

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

Chuang WY, Ströbel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Müller-Hermelink HK, Saruhan-Direskeneli G, Bugert P, Willcox N, Marx A.

J Autoimmun. 2014 Aug;52:122-9. doi: 10.1016/j.jaut.2013.12.006. Epub 2013 Dec 24.

PMID:
24373506
7.

Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood.

Wolff AS, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BE, Kisand K, Oláh E, Meloni A, Myhre AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A.

J Clin Immunol. 2013 Nov;33(8):1341-8. doi: 10.1007/s10875-013-9938-6. Epub 2013 Oct 26.

PMID:
24158785
8.

Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.

Klein R, Marx A, Ströbel P, Schalke B, Nix W, Willcox N.

Hum Immunol. 2013 Sep;74(9):1184-93. doi: 10.1016/j.humimm.2013.06.020. Epub 2013 Jun 18.

PMID:
23792059
9.

Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice.

Kärner J, Meager A, Laan M, Maslovskaja J, Pihlap M, Remm A, Juronen E, Wolff AS, Husebye ES, Podkrajšek KT, Bratanic N, Battelino T, Willcox N, Peterson P, Kisand K.

Clin Exp Immunol. 2013 Mar;171(3):263-72. doi: 10.1111/cei.12024.

10.

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

Gomez AM, Willcox N, Molenaar PC, Buurman W, Martinez-Martinez P, De Baets MH, Losen M.

Ann N Y Acad Sci. 2012 Dec;1274:48-59. doi: 10.1111/j.1749-6632.2012.06824.x. Review.

PMID:
23252897
11.

Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.

Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, McKee D, Simpfendorfer KR, Pirskanen-Matell R, Piehl F, Pan-Hammarstrom Q, Verschuuren JJ, Titulaer MJ, Niks EH, Marx A, Ströbel P, Tackenberg B, Pütz M, Maniaol A, Elsais A, Tallaksen C, Harbo HF, Lie BA, Raychaudhuri S, de Bakker PI, Melms A, Garchon HJ, Willcox N, Hammarstrom L, Seldin MF.

Ann Neurol. 2012 Dec;72(6):927-35. doi: 10.1002/ana.23691. Epub 2012 Oct 10.

12.

A comparison of radiological and computer navigation measurements of lower limb coronal alignment before and after total knee replacement.

Willcox NM, Clarke JV, Smith BR, Deakin AH, Deep K.

J Bone Joint Surg Br. 2012 Sep;94(9):1234-40. doi: 10.1302/0301-620X.94B9.28250.

PMID:
22933496
13.

A candidate gene for autoimmune myasthenia gravis.

Landouré G, Knight MA, Stanescu H, Taye AA, Shi Y, Diallo O, Johnson JO, Hernandez D, Traynor BJ, Biesecker LG; NIH Intramural Sequencing Center, Elkahloun A, Rinaldi C, Vincent A, Willcox N, Kleta R, Fischbeck KH, Burnett BG.

Neurology. 2012 Jul 24;79(4):342-7. Epub 2012 Jun 27.

14.

Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients.

Meloni A, Willcox N, Meager A, Atzeni M, Wolff AS, Husebye ES, Furcas M, Rosatelli MC, Cao A, Congia M.

J Clin Endocrinol Metab. 2012 Apr;97(4):1114-24. doi: 10.1210/jc.2011-2461. Epub 2012 Feb 16.

PMID:
22344197
15.

Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.

Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS.

J Clin Immunol. 2012 Apr;32(2):230-7. doi: 10.1007/s10875-011-9617-4. Epub 2011 Nov 30.

PMID:
22127461
16.

Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis.

Kakalacheva K, Maurer MA, Tackenberg B, Münz C, Willcox N, Lünemann JD.

Ann Neurol. 2011 Sep;70(3):508-14. doi: 10.1002/ana.22488.

PMID:
21905082
17.

Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications.

Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N.

Eur J Immunol. 2011 Jun;41(6):1517-27. doi: 10.1002/eji.201041253. Epub 2011 May 13. Review.

18.

The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation.

Hardie DL, Baldwin MJ, Naylor A, Haworth OJ, Hou TZ, Lax S, Curnow SJ, Willcox N, MacFadyen J, Isacke CM, Buckley CD.

Immunology. 2011 Jul;133(3):288-95. doi: 10.1111/j.1365-2567.2011.03437.x. Epub 2011 Apr 6.

19.

Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.

Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PA, Kuks JB, Roep BO, Vincent A, van der Maarel SM, van Dijk JG, Lang B, Verschuuren JJ.

J Clin Oncol. 2011 Mar 1;29(7):902-8. doi: 10.1200/JCO.2010.32.0440. Epub 2011 Jan 18.

PMID:
21245427
20.

The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond.

Marx A, Hohenberger P, Hoffmann H, Pfannschmidt J, Schnabel P, Hofmann HS, Wiebe K, Schalke B, Nix W, Gold R, Willcox N, Peterson P, Ströbel P.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S266-72. doi: 10.1097/JTO.0b013e3181f1f63f. Review.

21.

Thymoma and paraneoplastic myasthenia gravis.

Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, Ströbel P.

Autoimmunity. 2010 Aug;43(5-6):413-27. doi: 10.3109/08916930903555935. Review.

PMID:
20380583
22.

Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.

Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun-Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N, Meager A.

J Exp Med. 2010 Feb 15;207(2):299-308. doi: 10.1084/jem.20091669. Epub 2010 Feb 1.

23.

Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients.

Tackenberg B, Schlegel K, Happel M, Eienbröker C, Gellert K, Oertel WH, Meager A, Willcox N, Sommer N.

J Neuroimmunol. 2009 Nov 30;216(1-2):85-91. doi: 10.1016/j.jneuroim.2009.08.018. Epub 2009 Sep 24.

PMID:
19781791
24.

Evidence for the specificity for platelet HPA-1a alloepitope and the presenting HLA-DR52a of diverse antigen-specific helper T cell clones from alloimmunized mothers.

Rayment R, Kooij TW, Zhang W, Siebold C, Murphy MF, Allen D, Willcox N, Roberts DJ.

J Immunol. 2009 Jul 1;183(1):677-86. doi: 10.4049/jimmunol.0801473. Epub 2009 Jun 17.

25.

Prioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravis.

Kaur M, Schmeier S, MacPherson CR, Hofmann O, Hide WA, Taylor S, Willcox N, Bajic VB.

BMC Genomics. 2008 Oct 13;9:481. doi: 10.1186/1471-2164-9-481.

26.

The legacy of John Newsom-Davis (1932-2007).

Willcox N.

J Neuroimmunol. 2008 Sep 15;201-202:1. doi: 10.1016/j.jneuroim.2008.07.003. Epub 2008 Sep 5. No abstract available.

PMID:
18774182
27.

Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I.

Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Bøe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A.

J Clin Endocrinol Metab. 2008 Nov;93(11):4389-97. doi: 10.1210/jc.2008-0935. Epub 2008 Aug 26.

PMID:
18728167
28.

Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes.

Meager A, Peterson P, Willcox N.

Clin Exp Immunol. 2008 Oct;154(1):141-51. doi: 10.1111/j.1365-2249.2008.03739.x. Epub 2008 Aug 22.

29.

The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics.

Hill ME, Shiono H, Newsom-Davis J, Willcox N.

J Neuroimmunol. 2008 Sep 15;201-202:50-6. doi: 10.1016/j.jneuroim.2008.06.027. Epub 2008 Aug 22.

PMID:
18722675
30.

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

Maclennan CA, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D.

J Neuroimmunol. 2008 Sep 15;201-202:28-32. doi: 10.1016/j.jneuroim.2008.06.016. Epub 2008 Jul 26.

PMID:
18657869
31.

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens.

Ströbel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, Nix W, Schalke B, Kiefer R, Müller-Hermelink HK, Jaretzki Iii A, Newsom-Davis J, Marx A.

J Neuroimmunol. 2008 Sep 15;201-202:64-73. doi: 10.1016/j.jneuroim.2008.06.017. Epub 2008 Jul 25.

PMID:
18657325
32.

Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes.

Kisand K, Link M, Wolff AS, Meager A, Tserel L, Org T, Murumägi A, Uibo R, Willcox N, Trebusak Podkrajsek K, Battelino T, Lobell A, Kämpe O, Lima K, Meloni A, Ergun-Longmire B, Maclaren NK, Perheentupa J, Krohn KJ, Scott HS, Husebye ES, Peterson P.

Blood. 2008 Oct 1;112(7):2657-66. doi: 10.1182/blood-2008-03-144634. Epub 2008 Jul 7.

33.

Autoimmunizing mechanisms in thymoma and thymus.

Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, Dasgupta B, Morgan BP, Vincent A.

Ann N Y Acad Sci. 2008;1132:163-73. doi: 10.1196/annals.1405.021.

PMID:
18567866
34.

Myasthenia gravis seronegative for acetylcholine receptor antibodies.

Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N.

Ann N Y Acad Sci. 2008;1132:84-92. doi: 10.1196/annals.1405.020.

PMID:
18567857
35.

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.

Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A.

Brain. 2008 Jul;131(Pt 7):1940-52. doi: 10.1093/brain/awn092. Epub 2008 May 31.

36.

An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus.

Giraud M, Taubert R, Vandiedonck C, Ke X, Lévi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ.

Nature. 2007 Aug 23;448(7156):934-7. Epub 2007 Aug 8.

PMID:
17687331
37.

Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.

Leite MI, Jones M, Ströbel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N.

Am J Pathol. 2007 Sep;171(3):893-905. Epub 2007 Aug 3.

38.

Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).

Ströbel P, Murumägi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Müller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A.

J Pathol. 2007 Apr;211(5):563-71.

PMID:
17334980
39.

Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis.

Tackenberg B, Kruth J, Bartholomaeus JE, Schlegel K, Oertel WH, Willcox N, Hemmer B, Sommer N.

Eur J Immunol. 2007 Mar;37(3):849-63.

40.

Humanized mouse models for organ-specific autoimmune diseases.

Friese MA, Jensen LT, Willcox N, Fugger L.

Curr Opin Immunol. 2006 Dec;18(6):704-9. Epub 2006 Sep 27. Review.

PMID:
17008081
41.

Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N.

PLoS Med. 2006 Jul;3(7):e289.

42.

The value of animal models for drug development in multiple sclerosis.

Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L.

Brain. 2006 Aug;129(Pt 8):1940-52. Epub 2006 Apr 24. Review.

PMID:
16636022
43.

Autoantibodies in neuromuscular autoimmune disorders.

Lang B, Willcox N.

Expert Rev Clin Immunol. 2006 Mar;2(2):293-307. doi: 10.1586/1744666X.2.2.293.

PMID:
20477079
44.

Treatment of distal radial fractures with grafting and K-wiring.

Willcox N, Kurta I, Menez D.

Acta Orthop Belg. 2005 Feb;71(1):36-40.

PMID:
15792205
45.

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

Leite MI, Ströbel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A.

Ann Neurol. 2005 Mar;57(3):444-8.

PMID:
15732104
46.

HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome.

Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BP, Giphart MJ, Wintzen AR, Roep BO, Verschuuren JJ.

J Neuroimmunol. 2005 Feb;159(1-2):230-7. Epub 2004 Dec 24.

PMID:
15652424
47.

Control of autoimmunity by "epitope theft".

Kranc KR, Taylor AM, Willcox N, Fugger L.

Trends Mol Med. 2005 Jan;11(1):1-4. Review.

PMID:
15649815
48.

Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice.

Svendsen P, Andersen CB, Willcox N, Coyle AJ, Holmdahl R, Kamradt T, Fugger L.

J Immunol. 2004 Dec 1;173(11):7037-45.

49.

Delayed biodegradation of a meniscal screw.

Willcox N, Roberts S.

Arthroscopy. 2004 Jul;20 Suppl 2:20-2.

PMID:
15243418
50.

Lack of association between acetylcholine receptor epsilon polymorphisms and early-onset myasthenia gravis.

Bonifati DM, Willcox N, Vincent A, Beeson D.

Muscle Nerve. 2004 Mar;29(3):436-9.

PMID:
14981744

Supplemental Content

Loading ...
Support Center